Articles from Allurion Technologies, Inc.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 titled “Balloon Sealing and Fill Valve”. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the treatment of obesity that includes an enhanced valve for Balloon filling and an innovative mechanism that controls balloon opening. These patents are expected to provide protection through April 2043. With the issuance of these patents, the Company now has 22 patents issued in the U.S. and 64 patents issued globally.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price of $5.23 per share and will become exercisable immediately following the date of stockholder approval and expire on the fifth anniversary of receipt of such approval. The registered direct offering of common stock and the concurrent private placement of warrants are collectively referred to as the offering herein.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share in a registered direct offering. In addition, the Company will issue to the investors warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price of $5.23 per share and will become exercisable immediately following the date of stockholder approval and expire on the fifth anniversary of receipt of such approval. The registered direct offering of common stock and the concurrent private placement of warrants are collectively referred to as the offering herein.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology and the introduction of innovative features, particularly to the precision of the valve system that controls balloon opening. The patent is expected to provide protection through July 2039. With the issuance of this patent, the Company now has 20 patents issued in the U.S. and 59 patents issued globally.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Company’s runway through early 2026. The subscription agreement also includes an option to fund up to an additional $10 million in subsequent tranches. The private placement is expected to close on or about January 15, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company’s previously submitted plan to regain compliance with the NYSE’s continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”). The Company expects to have until March 1, 2026 to regain compliance with the NYSE’s Minimum Market Capitalization Standard.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average market capitalization of the Company was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and the Company’s last reported stockholders’ equity as of August 29, 2024 was less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program’s ongoing virtual guidance and support.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company’s international commercial sales and operations functions.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s common stock per the Notice was less than $1.00 per share over the consecutive 30 trading-day period ended August 8, 2024. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quarter ended June 30, 2024 and provided a business update.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase 14,406,508 Shares (the “Warrants” and, together with the Shares, the “Securities”) at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”).

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1s and other anti-obesity medications, such as treatment duration, side effects, and consequences of stopping their treatment. They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences:

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced three oral scientific presentations at the 12th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders – European Chapter (IFSO-EC) held in Vienna, Austria on 2-4 May 2024.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024. Management expects preliminary unaudited results for the period as follows:

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”). Proceeds will be used to repay in full the Company’s obligations under its existing term loan with Fortress Credit Corp., reducing the Company’s interest expense and increasing operational flexibility.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference, taking place on March 12 - 13, 2024, virtually. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present today, Wednesday, March 13, 2024 at 4:00 p.m. Eastern Time. Management will also participate in 1x1 meetings.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2023 on Thursday, March 21, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in the 44th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Tuesday, March 5, 2024 at 9:50 a.m. Eastern Time. Management will also participate in 1x1 meetings.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in the BTIG Snowbird Conference taking place on Monday, February 12 through Wednesday, February 14, 2024 in Snowbird. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will be available for investor 1x1 meetings.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for approximately 4 months, after which it self-empties and passes out naturally. It is proven to help patients lose an average of 10-15% of their body weight after approximately four months2. Studies show that on average, 96% of weight loss can be sustained 1 year after the balloon passes3.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss clinic chain.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced preliminary unaudited results for the fourth quarter and full year 2023. The Company also issued its preliminary 2024 outlook, reflecting an increased focus on driving sustained procedural volume growth ahead of key FDA milestones while reducing cost structure, optimizing capital structure, and accelerating the path to profitability.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany’s leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead commercialization of Allurion’s rapidly growing digital assets.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2023 and provided a business update.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will be participating in the Jefferies London Healthcare Conference taking place on November 14-16, 2023 in London. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Wednesday, November 15, 2023 at 9:30 a.m. GMT, and will be available for investor 1x1 meetings.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2023 on Monday, November 13, 2023. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced acceptance of five abstracts that will be presented at Obesity Week 2023, the annual meeting of The Obesity Society to be held in Dallas, Texas from October 14-17.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, has today unveiled Coach Iris, a new generative AI-powered health coach designed to enhance outcomes within the Allurion Program and maximize clinic efficiency. Built in close collaboration with leading global weight-management professionals and Allurion’s behavioral scientists, Coach Iris is intended to instantly expand the care team by providing always-on support, education, and motivation.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, today announced the completion of its previously announced business combination (the “Business Combination”) with Compute Health Acquisition Corp. (“Compute Health”) (NYSECPUH), a publicly traded special purpose acquisition company. Allurion is expected to commence trading of its common stock and public warrants on the New York Stock Exchange under the new ticker symbols “ALUR” and “ALUR WS,” respectively, on August 2, 2023. The Business Combination, which was approved by Compute Health’s stockholders on July 28, 2023, provides access to capital that will be used to drive Allurion’s growth initiatives.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, and Compute Health Acquisition Corp. (“Compute Health”) (NYSECPUH) today announced that Compute Health’s stockholders have approved all proposals related to the previously announced business combination (the “Business Combination”) between Compute Health and Allurion at a special meeting of Compute Health’s stockholders held on July 28, 2023. Approximately 99.8% of the votes cast on the Business Combination proposals by holders of Compute Health’s common stock, representing approximately 87.7% of Compute Health’s outstanding common stock, voted to approve the Business Combination, including approximately 58.2% of the outstanding shares of Compute Health’s Class A common stock (voting separately as a single class). The closing of the Business Combination is anticipated to occur on or about August 1, 2023, subject to the satisfaction of customary closing conditions. Following the closing, the combined company will operate as Allurion Technologies, Inc. and will be listed on the New York Stock Exchange, with its common stock and public warrants trading under the new ticker symbols “ALUR” and “ALUR WS,” respectively.

Compute Health Acquisition Corp. (“Compute Health”) (NYSE: CPUH, CPUH WS, CPUH.U) today announced that at a special meeting of Compute Health’s warrant holders held today (the "Warrant Holder Meeting"), the previously announced proposal to amend the warrant agreement that governs the outstanding warrants of Compute Health (the “Warrant Amendment”) was approved by its warrant holders. Approximately 89% of the votes cast at the Warrant Holder Meeting, including votes cast by holders of approximately 55% of Compute Health’s outstanding public warrants, voted to approve the Warrant Amendment.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, is pleased to announce two major additions to the team. Douglas Hudson has been appointed to the Board of Directors of Allurion Technologies Holdings, Inc., effective as of the anticipated consummation of the proposed business combination (the “Business Combination”) between Allurion and Compute Health Acquisition Corp. (“Compute Health”) (NYSECPUH), and Tomer Stavitsky has joined as Allurion’s new Vice President of Corporate Development.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, and Compute Health Acquisition Corp. (“Compute Health”) (NYSECPUH) , remind Compute Health’s stockholders to vote in favor of their previously announced proposed business combination (the “Business Combination”) at a Special Meeting (the “Special Meeting”) for stockholders of record as of July 3, 2023. All Compute Health stockholders, regardless of number of shares held, are encouraged to vote “FOR” the Business Combination and related proposals described in the definitive proxy statement and prospectus previously filed by the parties with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Special Meeting.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, and Compute Health Acquisition Corp. (“Compute Health”) (NYSECPUH) today announced updated terms to the warrant agreement (the “Warrant Agreement”) that governs the outstanding warrants of Compute Health.

Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the European Congress on Obesity exploring the use of a GLP-1 weight-loss medication with the Allurion Gastric Balloon Program to enhance patient outcomes.

Allurion, a company dedicated to ending obesity, has unveiled the findings of landmark behavioral science research that could pave the way for the expansion of text- and AI-based coaching.

Allurion, a company dedicated to ending obesity, announced today the launch of premium tiers for the Virtual Care Suite and the launch of its proprietary “My Daily Action” bundle. The bundle is available in 15 languages and includes a library of evidence-based weight-loss actions related to mindset and habits, movement, wellbeing, and nutrition and eating.

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, and Compute Health Acquisition Corp, a special purpose acquisition company (“Compute Health”) (NYSECPUH), today announced that they have entered into a definitive business combination agreement that will result in Allurion becoming a publicly listed company. Upon closing, the combined company (the “Company”) will be named Allurion Technologies, Inc. and its common stock (the “Common Stock”) is expected to be traded on the New York Stock Exchange under the symbol “ALUR”.